True North Therapeutics Lands $45,000,000 Series D Funding

  • Feed Type
  • Date
  • Company Name
    True North Therapeutics
  • Mailing Address
    951 Gateway Blvd. South San Francisco, CA 94080 USA
  • Company Description
    True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from the financing will be used to accelerate further development of its lead complement inhibitor, TNT009, for Cold Agglutinin Disease (CAD), as well as other rare diseases targeting the Complement system.
  • M&A Terms
  • Venture Investor
    HBM BioCapital
  • Venture Investor
    Redmile Group
  • Venture Investor
    Perceptive Advisors
  • Venture Investor
    Franklin Templeton

Trending on Xconomy